Theravance Biopharma Stock In The News
| TBPH Stock | USD 9.92 0.31 3.23% |
The tone or emotional content of news articles related to Theravance Biopharma can affect its prices. Positive news sentiment can lead to an increase in demand for Theravance Biopharma's stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Theravance Biopharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Theravance Biopharma. The specific impact of Theravance Biopharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Theravance Biopharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Theravance Biopharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Theravance Biopharma Backtesting and Theravance Biopharma Hype Analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.
Theravance |
Theravance Biopharma Today Top News and Investor Outlook
Theravance Biopharma Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Theravance and other traded companies coverage. We help investors stay connected with Theravance headlines for the 16th of April 2024 to make an informed investment decision based on correlating the impacts of news items on Theravance Stock performance. Please note that trading solely based on the Theravance Biopharma hype is not for everyone as timely availability and quick action are needed to avoid losses.Theravance Biopharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Theravance earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Theravance Biopharma that are available to investors today. That information is available publicly through Theravance media outlets and privately through word of mouth or via Theravance internal channels. However, regardless of the origin, that massive amount of Theravance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Theravance Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Theravance Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Theravance Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Theravance Biopharma alpha.
Theravance Largest EPS Surprises
Earnings surprises can significantly impact Theravance Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-26 | 2023-12-31 | -0.15 | -0.17 | -0.02 | 13 | ||
2023-02-27 | 2022-12-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2022-11-07 | 2022-09-30 | -0.18 | -0.21 | -0.03 | 16 | ||
2023-11-07 | 2023-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2023-08-07 | 2023-06-30 | -0.21 | -0.28 | -0.07 | 33 | ||
2021-11-03 | 2021-09-30 | -0.56 | -0.48 | 0.08 | 14 |
Theravance Biopharma Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Theravance Biopharma Stock. Current markets are slightly bearish. About 56% of major world exchanges and indexes are down. See today's market update for more information.
15th of April 2024
Strength Seen in Theravance Bio Can Its 7.6 percent Jump Turn into More Strength at zacks.com
10th of April 2024
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader Event to Discuss Ampreloxeti... at finance.yahoo.com
2nd of April 2024
Acquisition by Rhonda Farnum of 37500 shares of Theravance Biopharma subject to Rule 16b-3 at MacroaxisInsider
26th of March 2024
Theravance Biopharma Share Price Passes Below 50 Day Moving Average of 9.04 - MarketBeat at news.google.com
7th of March 2024
FY2026 EPS Estimates for Theravance Biopharma, Inc. Raised by Leerink Partnrs - MarketBeat at news.google.com
28th of February 2024
Theravance Biopharma, Inc. Q4 2023 Earnings Call Transcript at insidermonkey.com
27th of February 2024
Theravances Q4 Earnings Revenues Surpass Estimates at zacks.com
26th of February 2024
Theravance Biopharma GAAP EPS of -0.17 misses by 0.02, revenue of 17.6M beats by 0.03M at seekingalpha.com
22nd of February 2024
Disposition of 1254 shares by Rhonda Farnum of Theravance Biopharma at 8.71 subject to Rul... at zacks.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Theravance Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Theravance Biopharma's short interest history, or implied volatility extrapolated from Theravance Biopharma options trading.
Check out Theravance Biopharma Backtesting and Theravance Biopharma Hype Analysis. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.